S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:FTSV - Forty Seven Stock Price, Forecast & News

+2.37 (+5.58 %)
(As of 02/17/2020 09:56 AM ET)
Today's Range
Now: $44.81
50-Day Range
MA: $40.34
52-Week Range
Now: $44.81
Volume451,337 shs
Average Volume453,778 shs
Market Capitalization$1.89 billion
P/E RatioN/A
Dividend YieldN/A
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FTSV



Sales & Book Value

Annual SalesN/A
Book Value$4.29 per share


Net Income$-70,370,000.00


Market Cap$1.89 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to analyst estimates of $15.80 million. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

10 brokerages have issued twelve-month price objectives for Forty Seven's stock. Their forecasts range from $18.00 to $55.00. On average, they expect Forty Seven's stock price to reach $44.10 in the next twelve months. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (1/22/2020)
  • 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)

Has Forty Seven been receiving favorable news coverage?

Media headlines about FTSV stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Forty Seven earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Forty Seven.

Are investors shorting Forty Seven?

Forty Seven saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,200,000 shares, an increase of 6.3% from the January 15th total of 2,070,000 shares. Based on an average daily volume of 826,600 shares, the short-interest ratio is currently 2.7 days. Approximately 8.2% of the company's stock are sold short. View Forty Seven's Current Options Chain.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), Amarin (AMRN), TG Therapeutics (TGTX), GlycoMimetics (GLYC), NVIDIA (NVDA), AT&T (T), Exelixis (EXEL), Global Blood Therapeutics (GBT) and Trillium Therapeutics (TRIL).

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

Who are Forty Seven's major shareholders?

Forty Seven's stock is owned by many different of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (4.57%), FMR LLC (1.40%), Lord Abbett & CO. LLC (1.14%), State Street Corp (1.01%), Samlyn Capital LLC (0.65%) and Bourgeon Capital Management LLC (0.53%). Company insiders that own Forty Seven stock include Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View Institutional Ownership Trends for Forty Seven.

Which institutional investors are selling Forty Seven stock?

FTSV stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., UBS Group AG, Laurion Capital Management LP, Bank of America Corp DE, Bourgeon Capital Management LLC, Credit Suisse AG, Exane Asset Management and Regis Management CO LLC. Company insiders that have sold Forty Seven company stock in the last year include Chris H Takimoto, Irving Weissman, Mark Anthony Mccamish and Ravindra Majeti. View Insider Buying and Selling for Forty Seven.

Which institutional investors are buying Forty Seven stock?

FTSV stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Lord Abbett & CO. LLC, FMR LLC, Samlyn Capital LLC, Driehaus Capital Management LLC, State Street Corp, EAM Investors LLC and Monashee Investment Management LLC. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Insider Buying and Selling for Forty Seven.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $44.81.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $1.89 billion. The company earns $-70,370,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Forty Seven employs 57 workers across the globe.View Additional Information About Forty Seven.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com/.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]

MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel